IO Biotech, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD -96.93 M

IO Biotech, Inc. EBITDA is USD -96.93 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 8.66% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • IO Biotech, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -89.20 M, a 26.87% change year over year.
  • IO Biotech, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -70.31 M, a -12.73% change year over year.
  • IO Biotech, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -80.57 M.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)